Robert Bies - Publications

Affiliations: 
University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Pharmacy, Public Health, Pharmacology

82 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Reeves S, Bertrand J, Uchida H, Yoshida K, Otani Y, Ozer M, Liu KY, Bramon E, Bies R, Pollock BG, Howard R. Towards safer risperidone prescribing in Alzheimer's disease. The British Journal of Psychiatry : the Journal of Mental Science. 1-8. PMID 33176899 DOI: 10.1192/bjp.2020.225  0.92
2019 Koizumi T, Suzuki T, Pillai NS, Bies RR, Takeuchi H, Yoshimura K, Mimura M, Uchida H. Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology. Journal of Psychiatric Research. 117: 1-6. PMID 31254838 DOI: 10.1016/j.jpsychires.2019.06.019  0.56
2019 Ozawa C, Bies RR, Pillai N, Suzuki T, Mimura M, Uchida H. Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial. Journal of Clinical Psychopharmacology. PMID 31188232 DOI: 10.1097/JCP.0000000000001046  0.36
2016 Sakurai H, Suzuki T, Bies RR, Pollock BG, Mimura M, Kapur S, Uchida H. Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. The Journal of Clinical Psychiatry. 77: 1381-1390. PMID 27788310 DOI: 10.4088/JCP.15m10490  0.92
2016 Ho T, Pollock BG, Mulsant BH, Schantz O, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Drye LT, Munro CA, Shade DM, Lyketsos C, Bies R. R-and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. British Journal of Clinical Pharmacology. PMID 27145364 DOI: 10.1111/bcp.12997  0.92
2016 Lee J, Bies R, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Quantifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approach. The Journal of Clinical Psychiatry. PMID 27136679 DOI: 10.4088/JCP.14m09714  0.64
2016 Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. Human Psychopharmacology. PMID 27060853 DOI: 10.1002/hup.2532  0.68
2016 Flockhart D, Bies RR, Gastonguay MR, Schwartz SL. Big Data: Challenges and opportunities for clinical pharmacology. British Journal of Clinical Pharmacology. 81: 804-6. PMID 26845397 DOI: 10.1111/bcp.12896  0.44
2016 Flockhart D, Bies RR, Gastonguay MR, Schwartz SL. Big Data: Challenges and opportunities for clinical pharmacology British Journal of Clinical Pharmacology. DOI: 10.1111/bcp.12896  0.64
2015 Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Shade DM, Lyketsos CG. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26611790 DOI: 10.1007/s10928-015-9457-6  0.64
2015 Tsuboi T, Bies RR, Suzuki T, Takeuchi H, Nakajima S, Graff-Guerrero A, Mamo DC, Caravaggio F, Plitman E, Mimura M, Pollock BG, Uchida H. Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study. Pharmacopsychiatry. PMID 26506574 DOI: 10.1055/s-0035-1565070  0.64
2015 Sawyer MB, Pituskin E, Damaraju S, Bies RR, Vos LJ, Prado CM, Kuzma M, Scarfe AG, Clemons M, Tonkin K, Au HJ, Koski S, Joy AA, Smylie M, King K, et al. A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. Clinical Breast Cancer. PMID 26452313 DOI: 10.1016/j.clbc.2015.09.006  0.64
2015 Velez de Mendizabal N, Jackson K, Eastwood B, Swanson S, Bender DM, Lowe S, Bies RR. A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats. Journal of Pharmacokinetics and Pharmacodynamics. 42: 721-33. PMID 26395999 DOI: 10.1007/s10928-015-9448-7  0.64
2015 Lee J, Bies R, Bhaloo A, Powell V, Remington G. Clozapine and anemia: a 2-year follow-up study. The Journal of Clinical Psychiatry. PMID 26301364 DOI: 10.4088/JCP.14m09143  0.64
2015 Lee J, Takeuchi H, Fervaha G, Powell V, Bhaloo A, Bies R, Remington G. The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study. Journal of Clinical Psychopharmacology. 35: 510-6. PMID 26267420 DOI: 10.1097/JCP.0000000000000387  0.68
2015 Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Mamo DC, Graff-Guerrero A. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. Schizophrenia Bulletin. PMID 26221049 DOI: 10.1093/schbul/sbv106  0.64
2015 Akil A, Zhang Q, Mumaw CL, Raiker N, Yu J, Velez de Mendizabal N, Haneline LS, Robertson KA, Skiles J, Diaz-Ricart M, Carreras E, Renbarger J, Hanash S, Bies RR, Paczesny S. Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26172478 DOI: 10.1016/j.bbmt.2015.07.004  0.68
2015 Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Clinical Pharmacokinetics. PMID 25971243 DOI: 10.1007/s40262-015-0275-1  0.68
2015 Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. Schizophrenia Research. 164: 149-54. PMID 25864950 DOI: 10.1016/j.schres.2015.03.025  0.92
2015 Yang QJ, Jerath A, Bies RR, W?sowicz M, Pang KS. Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment. Biopharmaceutics & Drug Disposition. 36: 294-307. PMID 25704361 DOI: 10.1002/bdd.1941  0.68
2015 Li CH, Sherer EA, Lewis LD, Bies RR. Clinical trial simulation to evaluate population pharmacokinetics and food effect: capturing abiraterone and nilotinib exposures. Journal of Clinical Pharmacology. 55: 556-62. PMID 25511575 DOI: 10.1002/jcph.449  0.68
2015 Vélez de Mendizábal N, Jones DR, Jahn A, Bies RR, Brown JW. Nicotine and cotinine exposure from electronic cigarettes: a population approach. Clinical Pharmacokinetics. 54: 615-26. PMID 25503588 DOI: 10.1007/s40262-014-0221-7  0.68
2015 Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, MasaruMimura, Uchida H. Corrigendum to Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data [Schizophr. Res. 150 (2-3), November 2013, Pages 373-379], DOI: 10.1016/j.schres.2013.08.033 Schizophrenia Research. 162: 296. DOI: 10.1016/j.schres.2015.01.011  0.68
2014 Jin Y, Bies R, Gastonguay MR, Wang Y, Stockbridge N, Gobburu J, Madabushi R. Predicted impact of various clinical practice strategies on cardiovascular risk for the treatment of hypertension: a clinical trial simulation study. Journal of Pharmacokinetics and Pharmacodynamics. 41: 693-704. PMID 25326066 DOI: 10.1007/s10928-014-9394-9  0.52
2014 Li CH, Stratford RE, Velez de Mendizabal N, Cremers TI, Pollock BG, Mulsant BH, Remington G, Bies RR. Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. Journal of Translational Medicine. 12: 203. PMID 25142323 DOI: 10.1186/1479-5876-12-203  0.92
2014 Takeuchi H, Suzuki T, Bies RR, Remington G, Watanabe K, Mimura M, Uchida H. Dose reduction of risperidone and olanzapine and estimated dopamine Dâ‚‚ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. The Journal of Clinical Psychiatry. 75: 1209-14. PMID 25099201 DOI: 10.4088/JCP.13m08841  0.64
2014 Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G. Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. The Journal of Clinical Psychiatry. 75: 506-11. PMID 24569099 DOI: 10.4088/JCP.13m08695  0.64
2014 Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Mimura M, Uchida H. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophrenia Research. 153: 184-8. PMID 24491908 DOI: 10.1016/j.schres.2014.01.017  0.92
2013 Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophrenia Research. 150: 373-9. PMID 24028745 DOI: 10.1016/j.schres.2013.08.033  0.92
2013 Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Journal of Clinical Psychopharmacology. 33: 682-5. PMID 23899638 DOI: 10.1097/JCP.0b013e3182979a0a  0.92
2013 Empey PE, de Mendizabal NV, Bell MJ, Bies RR, Anderson KB, Kochanek PM, Adelson PD, Poloyac SM. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. Critical Care Medicine. 41: 2379-87. PMID 23896831 DOI: 10.1097/CCM.0b013e318292316c  0.68
2013 Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia Bulletin. 39: 993-8. PMID 23821768 DOI: 10.1093/schbul/sbt090  0.64
2013 Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A, Mimura M, Uchida H. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 45: 178-82. PMID 23727135 DOI: 10.1016/j.pnpbp.2013.05.010  0.92
2013 Li CH, Pollock BG, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, Sorisio D, Bies RR. Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study. Journal of Clinical Pharmacology. 53: 234-9. PMID 23436269 DOI: 10.1177/0091270012445793  0.92
2013 Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenetics and Genomics. 23: 29-33. PMID 23188068 DOI: 10.1097/FPC.0b013e32835b16d8  0.68
2013 Stevens J, Bies RR, Shekhar A, Anand A. Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression. British Journal of Clinical Pharmacology. 75: 791-8. PMID 22846159 DOI: 10.1111/j.1365-2125.2012.04398.x  0.68
2013 Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophrenia Bulletin. 39: 564-74. PMID 22290266 DOI: 10.1093/schbul/sbr189  0.92
2012 Wessels AM, Jin Y, Pollock BG, Frank E, Lange AC, Vrijens B, Fagiolini A, Kupfer DJ, Rucci P, Kepple G, Anderton J, Buttenfield J, Bies RR. Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' study. International Clinical Psychopharmacology. 27: 291-7. PMID 22990142 DOI: 10.1097/YIC.0b013e3283597678  0.68
2012 Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. Journal of Pharmacokinetics and Pharmacodynamics. 39: 393-414. PMID 22767341 DOI: 10.1007/s10928-012-9258-0  0.68
2012 Jin Y, Bies R, Gastonguay MR, Stockbridge N, Gobburu J, Madabushi R. Misclassification and discordance of measured blood pressure from patient's true blood pressure in current clinical practice: a clinical trial simulation case study. Journal of Pharmacokinetics and Pharmacodynamics. 39: 283-94. PMID 22569889 DOI: 10.1007/s10928-012-9250-8  0.52
2012 Aregbe AO, Sherer EA, Egorin MJ, Scher HI, Solit DB, Ramanathan RK, Ramalingam S, Belani CP, Ivy PS, Bies RR. Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology. 70: 201-5. PMID 22450873 DOI: 10.1007/s00280-012-1859-1  0.68
2012 Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Therapeutic Drug Monitoring. 34: 182-7. PMID 22377743 DOI: 10.1097/FTD.0b013e3182489a6f  0.92
2012 Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ. Resampling phase III data to assess phase II trial designs and endpoints. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2309-15. PMID 22287601 DOI: 10.1158/1078-0432.CCR-11-1815  0.32
2012 Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 37: 182-7. PMID 22230651 DOI: 10.1016/j.pnpbp.2011.12.013  0.92
2012 Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK, Pollock BG, Mulsant BH, Bies RR. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 20: 53-60. PMID 21422906 DOI: 10.1097/JGP.0b013e3182118318  0.92
2011 Feng Y, Gastonguay MR, Pollock BG, Frank E, Kepple GH, Bies RR. Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy. Neuropsychiatric Disease and Treatment. 7: 117-25. PMID 21552314 DOI: 10.2147/NDT.S15921  0.92
2011 Poloyac SM, Empey KM, Rohan LC, Skledar SJ, Empey PE, Nolin TD, Bies RR, Gibbs RB, Folan M, Kroboth PD. Core competencies for research training in the clinical pharmaceutical sciences. American Journal of Pharmaceutical Education. 75: 27. PMID 21519417  0.68
2011 Bigos KL, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Molecular Psychiatry. 16: 620-5. PMID 21519338 DOI: 10.1038/mp.2011.38  0.68
2011 Han K, Bies R, Johnson H, Capitano B, Venkataramanan R. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. Clinical Pharmacokinetics. 50: 201-14. PMID 21294597 DOI: 10.2165/11538690-000000000-00000  0.32
2011 Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. Journal of Clinical Pharmacology. 51: 1587-91. PMID 21209243 DOI: 10.1177/0091270010387604  0.68
2010 Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. Journal of Clinical Psychopharmacology. 30: 683-7. PMID 21105282 DOI: 10.1097/JCP.0b013e3181fa05bb  0.68
2010 Lenze EJ, Goate AM, Nowotny P, Dixon D, Shi P, Bies RR, Lotrich FK, Rollman BL, Shear MK, Thompson PA, Andreescu C, Pollock BG. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. Journal of Clinical Psychopharmacology. 30: 672-7. PMID 21105279 DOI: 10.1097/JCP.0b013e3181fc2bef  0.68
2010 Bender G, Florian JA, Bramwell S, Field MJ, Tan KK, Marshall S, DeJongh J, Bies RR, Danhof M. Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. The Journal of Pharmacology and Experimental Therapeutics. 334: 599-608. PMID 20444880 DOI: 10.1124/jpet.110.166074  0.68
2010 Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. Journal of Clinical Pharmacology. 50: 73-80. PMID 19843655 DOI: 10.1177/0091270009343694  0.92
2010 Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, Müller DJ, Kennedy JL, Forgione RN, Kirshner M, Kepple G, Fagiolini A, Kupfer DJ, Bies RR. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. Journal of Clinical Pharmacology. 50: 62-72. PMID 19841156 DOI: 10.1177/0091270009337946  0.68
2009 Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gender Medicine. 6: 522-43. PMID 20114004 DOI: 10.1016/j.genm.2009.12.004  0.92
2009 Bender G, Gosset J, Florian J, Tan K, Field M, Marshall S, DeJongh J, Bies R, Danhof M. Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design. Pharmaceutical Research. 26: 2259-69. PMID 19669867 DOI: 10.1007/s11095-009-9942-y  0.68
2009 Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B, Pollock BG, Mulsant BH, Bies RR. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Therapeutic Drug Monitoring. 31: 360-6. PMID 19349931 DOI: 10.1097/FTD.0b013e31819c7037  0.92
2009 Jin Y, Pollock BG, Frank E, Florian J, Kirshner M, Fagiolini A, Kupfer DJ, Gastonguay MR, Kepple G, Feng Y, Bies RR. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. Journal of Clinical Pharmacology. 49: 176-84. PMID 19179296 DOI: 10.1177/0091270008327538  0.68
2009 Kamarck TW, Haskett RF, Muldoon M, Flory JD, Anderson B, Bies R, Pollock B, Manuck SB. Citalopram intervention for hostility: results of a randomized clinical trial. Journal of Consulting and Clinical Psychology. 77: 174-88. PMID 19170463 DOI: 10.1037/a0014394  0.68
2008 Lenze EJ, Sheffrin M, Driscoll HC, Mulsant BH, Pollock BG, Dew MA, Lotrich F, Devlin B, Bies R, Reynolds CF. Incomplete response in late-life depression: getting to remission. Dialogues in Clinical Neuroscience. 10: 419-30. PMID 19170399  0.68
2008 Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Therapeutic Drug Monitoring. 30: 674-81. PMID 19057371 DOI: 10.1097/00003246-200512002-00603  0.92
2008 Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. British Journal of Clinical Pharmacology. 66: 629-39. PMID 18771484 DOI: 10.1111/j.1365-2125.2008.03276.x  0.92
2008 Frank E, Cassano GB, Rucci P, Fagiolini A, Maggi L, Kraemer HC, Kupfer DJ, Pollock B, Bies R, Nimgaonkar V, Pilkonis P, Shear MK, Thompson WK, Grochocinski VJ, Scocco P, et al. Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. Clinical Trials (London, England). 5: 253-61. PMID 18559415 DOI: 10.1177/1740774508091965  0.68
2008 Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G. Anticholinergic activity of 107 medications commonly used by older adults. Journal of the American Geriatrics Society. 56: 1333-41. PMID 18510583 DOI: 10.1111/j.1532-5415.2008.01737.x  0.68
2008 Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 3221-5. PMID 18463627 DOI: 10.1038/npp.2008.52  0.68
2008 Bies RR, Gastonguay MR, Schwartz SL. Mathematics for understanding disease Clinical Pharmacology and Therapeutics. 83: 904-908. PMID 18388872 DOI: 10.1038/clpt.2008.53  0.68
2008 Bigos KL, Chew ML, Bies RR. Pharmacokinetics in geriatric psychiatry. Current Psychiatry Reports. 10: 30-6. PMID 18269892  0.92
2008 Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology. 48: 157-65. PMID 18199892 DOI: 10.1177/0091270007310385  0.68
2007 Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3302-11. PMID 17545536 DOI: 10.1158/1078-0432.CCR-06-2345  0.68
2006 Bigos KL, Bies RR, Pollock BG. Population pharmacokinetics in geriatric psychiatry. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 993-1003. PMID 17138806 DOI: 10.1097/01.JGP.0000224330.73063.6c  0.92
2006 Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S, Gharabawi G. A model of anticholinergic activity of atypical antipsychotic medications. Schizophrenia Research. 88: 63-72. PMID 16928430 DOI: 10.1016/j.schres.2006.07.011  0.68
2006 Feng Y, Green B, Duffull SB, Kane-Gill SL, Bobek MB, Bies RR. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. British Journal of Clinical Pharmacology. 62: 165-76. PMID 16842391 DOI: 10.1111/j.1365-2125.2006.02650.x  0.44
2006 Lotrich FE, Bies RR, Smith GS, Pollock BG. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. Journal of Psychopharmacology (Oxford, England). 20: 33-40. PMID 16785268 DOI: 10.1177/1359786806066044  0.92
2006 Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF, Bies RR. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British Journal of Clinical Pharmacology. 61: 558-69. PMID 16669849 DOI: 10.1111/j.1365-2125.2006.02629.x  0.68
2006 Bies RR, Muldoon MF, Pollock BG, Manuck S, Smith G, Sale ME. A genetic algorithm-based, hybrid machine learning approach to model selection. Journal of Pharmacokinetics and Pharmacodynamics. 33: 195-221. PMID 16565924 DOI: 10.1007/s10928-006-9004-6  0.92
2005 Bies RR, Mulsant BH, Rosen J, Huber KA, Wilson NL, Kirshner MA, Pollock BG. Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. The American Journal of Geriatric Pharmacotherapy. 3: 87-91. PMID 16129385 DOI: 10.1016/j.amjopharm.2005.07.002  0.68
2005 Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology. 178: 268-75. PMID 15365685 DOI: 10.1007/s00213-004-2006-4  0.68
2004 Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ, Pollock BG. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. Journal of Clinical Pharmacology. 44: 1352-9. PMID 15545305 DOI: 10.1177/0091270004269647  0.92
2003 Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Frye RF. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. Clinical Pharmacology and Therapeutics. 74: 555-68. PMID 14663458 DOI: 10.1016/j.clpt.2003.09.003  0.44
2003 Bies RR, Bigos KL, Pollock BG. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. The Journal of Gender-Specific Medicine : Jgsm : the Official Journal of the Partnership For Women's Health At Columbia. 6: 12-20. PMID 14513571  0.92
2002 Bies RR, Gastonguay MR, Coley KC, Kroboth PD, Pollock BG. Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 696-705. PMID 12427578 DOI: 10.1097/00019442-200211000-00008  0.68
Show low-probability matches.